Akcea Therapeutics Announces New Appointments to its Board of Directors
“On behalf of the Akcea Board and the entire Akcea team, we thank Chris for his leadership and dedicated service to Akcea during a period of many significant advancements including launching TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen). Lynne has been an active board member who is very familiar with our business operations and goals and is the ideal candidate to guide our work as we plan for success in the years ahead,” said
Ms. Parshall is also currently a director and senior strategic advisor to
“As a member of the Akcea Board since its founding, I have an in-depth understanding of the Company’s business model and strong commercial and development capabilities. I also have a deep understanding of our products and the needs of the patient and clinician communities we serve. I am honored to accept this new role as chair of the Board and look forward to continuing to support the outstanding Akcea team as we plan for many new opportunities moving forward,” said Ms. Parshall.
Ms. Yanni was vice president and chief licensing officer at
“Barbara is highly regarded for her strong business background, deep knowledge of the pharmaceutical and biotechnology industries and extensive business development background. She will play a central role in helping us achieve our business objectives in the years ahead and we are pleased to welcome her to our board,” Dr. McDevitt added.
With the addition of Ms. Yanni, Akcea has now increased the authorized number of members of the Board to 10 and increased the number of independent board members from six to seven.
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akcea’s drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in Akcea’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.
In this press release, unless the context requires otherwise, “Ionis,” “Akcea,” “Company,” “Companies,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc., Akcea Therapeutics®, TEGSEDI® and WAYLIVRA® are trademarks of Akcea Therapeutics, Inc.
Akcea Investor Contact:
Vice President, Corporate Communications and Investor Relations
Akcea Media Contact:
T: 212 253-8881
Source: Akcea Therapeutics, Inc.